NCT00670566View on ClinicalTrials.gov

Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

503

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

March 31, 2009

Conditions

Hypertension

Interventions

DRUG

irbesartan/hydrochlorothiazide

50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY